Selective Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Attenuates High-Fat Diet-Induced Hepatic Steatosis in Mice

References

• YounossiZM, BlissettD, BlissettR, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577–1586. doi:10.1002/hep.2878527543837
   PubMed Web of Science ®Google Scholar
• FazelY, KoenigAB, SayinerM, GoodmanZD, YounossiZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65(8):1017–1025. doi:10.1016/j.metabol.2016.01.01226997539
   PubMed Web of Science ®Google Scholar
• FarrellGC, WongVW, ChitturiS. NAFLD in Asia – as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10(5):307–318. doi:10.1038/nrgastro.2013.3423458891
   PubMed Web of Science ®Google Scholar
• ChalasaniN, YounossiZ, LavineJE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–1609. doi:10.1053/j.gastro.2012.04.00122656328
   PubMed Web of Science ®Google Scholar
• SinghS, AllenAM, WangZ, ProkopLJ, MuradMH, LoombaR. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–654.e641–649. doi:10.1016/j.cgh.2014.04.014
   Web of Science ®Google Scholar
• FriedmanSL, Neuschwander-TetriBA, RinellaM, SanyalAJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922. doi:10.1038/s41591-018-0104-929967350
   PubMed Web of Science ®Google Scholar
• MonettiM, LevinMC, WattMJ, et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab. 2007;6(1):69–78. doi:10.1016/j.cmet.2007.05.00517618857
   PubMed Web of Science ®Google Scholar
• LiaoW, HuiTY, YoungSG, DavisRA. Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER. J Lipid Res. 2003;44(5):978–985. doi:10.1194/jlr.M300020-JLR20012588952
   PubMed Web of Science ®Google Scholar
• CusiK. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142(4):711–725. e716. doi:10.1053/j.gastro.2012.02.00322326434
   PubMed Web of Science ®Google Scholar
• BrilF, LomonacoR, OrsakB, et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology. 2014;59(6):2178–2187. doi:10.1002/hep.2698824777953
   PubMed Web of Science ®Google Scholar
• StojsavljevicS, PalcicMG, JukicLV, DuvnjakLS, DuvnjakM. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(48):18070–18091. doi:10.3748/wjg.v20.i48.1807025561778
   PubMed Web of Science ®Google Scholar
• OdermattA, ArnoldP, StaufferA, FreyBM, FreyFJ. The N-terminal anchor sequences of 11beta-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J Biol Chem. 1999;274(40):28762–28770. doi:10.1074/jbc.274.40.2876210497248
   PubMed Web of Science ®Google Scholar
• RahimiL, RajpalA, Ismail-BeigiF. Glucocorticoid-induced fatty liver disease. Diabetes Metab Syndr Obes. 2020;13:1133–1145. doi:10.2147/dmso.s24737932368109
   PubMed Web of Science ®Google Scholar
• PatersonJM, MortonNM, FievetC, et al. Metabolic syndrome without obesity: hepatic overexpression of 11 beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A. 2004;101(18):7088–7093. doi:10.1073/pnas.030552410115118095
   PubMed Web of Science ®Google Scholar
• MasuzakiH, PatersonJ, ShinyamaH, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294(5549):2166–2170. doi:10.1126/science.106628511739957
   PubMed Web of Science ®Google Scholar
• CandiaR, RiquelmeA, BaudrandR, et al. Overexpression of 11 beta-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease. Liver Int. 2012;32(3):392–399. doi:10.1111/j.1478-3231.2011.02685.x22136330
   PubMed Web of Science ®Google Scholar
• WangL, LiuJ, ZhangA, et al. BVT.2733, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, attenuates obesity and inflammation in diet-induced obese mice. PLoS One. 2012;7(7):e40056. doi:10.1371/journal.pone.004005622768329
   PubMed Web of Science ®Google Scholar
• HuangM, LiuJ, ShengY, et al. 11β-hydroxysteroid dehydrogenase type 1 inhibitor attenuates high-fat diet induced cardiomyopathy. J Mol Cell Cardiol. 2018;125:106–116. doi:10.1016/j.yjmcc.2018.10.00230291912
   PubMed Web of Science ®Google Scholar
• BerthiaumeM, LaplanteM, FestucciaWT, BergerJP, ThieringerR, DeshaiesY. Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats. Int J Obes (Lond). 2009;33(5):601–604. doi:10.1038/ijo.2009.3319223847
   PubMed Web of Science ®Google Scholar
• KohEH, KimAR, KimH, et al. 11β-HSD1 reduces metabolic efficacy and adiponectin synthesis in hypertrophic adipocytes. J Endocrinol. 2015;225(3):147–158. doi:10.1530/joe-15-011725869616
   PubMed Web of Science ®Google Scholar
• YuanX, LiH, BaiH, et al. The 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against the insulin resistance and hepatic steatosis in db/db mice. Eur J Pharmacol. 2016;788:140–151. doi:10.1016/j.ejphar.2016.05.03427242185
   PubMed Web of Science ®Google Scholar
• StefanN, RamsauerM, JordanP, et al. Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):406–416. doi:10.1016/s2213-8587(13)70170-024795254
   PubMed Web of Science ®Google Scholar
• HarnoE, CottrellEC, YuA, et al. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors still improve metabolic phenotype in male 11β-HSD1 knockout mice suggesting off-target mechanisms. Endocrinology. 2013;154(12):4580–4593. doi:10.1210/en.2013-161324169553
   PubMed Web of Science ®Google Scholar
• ZhaoP, WongKI, SunX, et al. TBK1 at the crossroads of inflammation and energy homeostasis in adipose tissue. Cell. 2018;172(4):731–743.e712. doi:10.1016/j.cell.2018.01.00729425491
   PubMed Web of Science ®Google Scholar
• BarfT, VallgårdaJ, EmondR, et al. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J Med Chem. 2002;45(18):3813–3815. doi:10.1021/jm025530f12190302
   PubMed Web of Science ®Google Scholar
• WangSJ, BirtlesS, de SchoolmeesterJ, et al. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia. 2006;49(6):1333–1337. doi:10.1007/s00125-006-0239-y16612591
   PubMed Web of Science ®Google Scholar
• LiG, Hernandez-OnoA, CrookeRM, GrahamMJ, GinsbergHN. Effects of antisense-mediated inhibition of 11β-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism. J Lipid Res. 2011;52(5):971–981. doi:10.1194/jlr.M01374821364201
   PubMed Web of Science ®Google Scholar
• FigarolaJL, SinghalP, RahbarS, GugiuBG, AwasthiS, SinghalSS. COH-SR4 reduces body weight, improves glycemic control and prevents hepatic steatosis in high fat diet-induced obese mice. PLoS One. 2013;8(12):e83801. doi:10.1371/journal.pone.008380124376752
   PubMed Web of Science ®Google Scholar
• GaidhuMP, AnthonyNM, PatelP, HawkeTJ, CeddiaRB. Dysregulation of lipolysis and lipid metabolism in visceral and subcutaneous adipocytes by high-fat diet: role of ATGL, HSL, and AMPK. Am J Physiol Cell Physiol. 2010;298(4):C961–C971. doi:10.1152/ajpcell.00547.200920107043
   PubMed Web of Science ®Google Scholar
• SuQ, KumarV, SudN, MahatoRI. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. Adv Drug Deliv Rev. 2018;129:54–63. doi:10.1016/j.addr.2018.01.00929391222
   PubMed Web of Science ®Google Scholar
• JainA, BarveA, ZhaoZ, et al. Targeted delivery of an siRNA/PNA hybrid nanocomplex reverses carbon tetrachloride-induced liver fibrosis. Adv Ther (Weinh). 2019;2(8):1900046. doi:10.1002/adtp.20190004633072857
   PubMedGoogle Scholar
• WilliamsCD, StengelJ, AsikeMI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–131. doi:10.1053/j.gastro.2010.09.03820858492
   PubMed Web of Science ®Google Scholar
• BellentaniS, SaccoccioG, MasuttiF, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132(2):112–117. doi:10.7326/0003-4819-132-2-200001180-0000410644271
   PubMed Web of Science ®Google Scholar
• ThamerC, MachannJ, HaapM, et al. Intrahepatic lipids are predicted by visceral adipose tissue mass in healthy subjects. Diabetes Care. 2004;27(11):2726–2729. doi:10.2337/diacare.27.11.272615505012
   PubMed Web of Science ®Google Scholar
• ZhangX, JiX, WangQ, LiJZ. New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Protein Cell. 2018;9(2):164–177. doi:10.1007/s13238-017-0436-028643267
   PubMed Web of Science ®Google Scholar
• van der PoortenD, MilnerKL, HuiJ, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008;48(2):449–457. doi:10.1002/hep.2235018627003
   PubMed Web of Science ®Google Scholar
• AlbertsP, EngblomL, EdlingN, et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia. 2002;45(11):1528–1532. doi:10.1007/s00125-002-0959-612436336
   PubMed Web of Science ®Google Scholar
• VeilleuxA, RhéaumeC, DarisM, TchernofA. Omental adipose tissue 11β-HSD1 oxoreductase activity, body fat distribution and metabolic alterations in women. J Clin Endocrinol Metab. 2009;94(9):3550–3557. doi:10.1210/jc.2008-201119567539
   PubMed Web of Science ®Google Scholar
• BujalskaIJ, GathercoleLL, TomlinsonJW, et al. A novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. J Endocrinol. 2008;197(2):297–307. doi:10.1677/joe-08-005018434359
   PubMed Web of Science ®Google Scholar
• MorganSA, McCabeEL, GathercoleLL, et al. 11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. Proc Natl Acad Sci U S A. 2014;111(24):E2482–2491. doi:10.1073/pnas.132368111124889609
   PubMed Web of Science ®Google Scholar
• WangY, YanC, LiuL, et al. 11β-Hydroxysteroid dehydrogenase type 1 shRNA ameliorates glucocorticoid-induced insulin resistance and lipolysis in mouse abdominal adipose tissue. Am J Physiol Endocrinol Metab. 2015;308(1):E84–95. doi:10.1152/ajpendo.00205.201425389364
   PubMed Web of Science ®Google Scholar
• MortonNM, PatersonJM, MasuzakiH, et al. Novel adipose tissue–mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1–deficient mice. Diabetes. 2004;53(4):931–938. doi:10.2337/diabetes.53.4.93115047607
   PubMed Web of Science ®Google Scholar
• IbrahimMM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11(1):11–18. doi:10.1111/j.1467-789X.2009.00623.x19656312
   PubMed Web of Science ®Google Scholar
• LaveryGG, ZielinskaAE, GathercoleLL, et al. Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1. Endocrinology. 2012;153(7):3236–3248. doi:10.1210/en.2012-101922555437
   PubMed Web of Science ®Google Scholar
• LarnerDP, MorganSA, GathercoleLL, et al. Male 11β-HSD1 knockout mice fed trans-fats and fructose are not protected from metabolic syndrome or nonalcoholic fatty liver disease. Endocrinology. 2016;157(9):3493–3504. doi:10.1210/en.2016-135727384305
   PubMed Web of Science ®Google Scholar
• VillenaJA, RoyS, Sarkadi-NagyE, KimKH, SulHS. Desnutrin, an adipocyte gene encoding a novel patatin domain-containing protein, is induced by fasting and glucocorticoids: ectopic expression of desnutrin increases triglyceride hydrolysis. J Biol Chem. 2004;279(45):47066–47075. doi:10.1074/jbc.M40385520015337759
   PubMed Web of Science ®Google Scholar
• MacfarlaneDP, ForbesS, WalkerBR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol. 2008;197(2):189–204. doi:10.1677/JOE-08-005418434349
   PubMed Web of Science ®Google Scholar
• CampbellJE, PeckettAJ, D’SouzaAM, HawkeTJ, RiddellMC. Adipogenic and lipolytic effects of chronic glucocorticoid exposure. Am J Physiol Cell Physiol. 2011;300(1):C198–C209. doi:10.1152/ajpcell.00045.201020943959
   PubMed Web of Science ®Google Scholar
• ZhangXQ, XuCF, YuCH, ChenWX, LiYM. Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(7):1768–1776. doi:10.3748/wjg.v20.i7.176824587654
   PubMed Web of Science ®Google Scholar
• LebeaupinC, ValléeD, HazariY, HetzC, ChevetE, Bailly-MaitreB. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2018;69(4):927–947. doi:10.1016/j.jhep.2018.06.00829940269
   PubMed Web of Science ®Google Scholar
• LiC, XiaJ, ZhuW, et al. Systemic overexpression of the 11β‑HSD1 promotes endoplasmic reticulum stress in multiple tissues and the development of metabolic syndrome in mice. Mol Med Rep. 2017;16(5):7738–7744. doi:10.3892/mmr.2017.753028944856
   PubMed Web of Science ®Google Scholar
• ZouX, RamachandranP, KendallTJ, et al. 11Beta-hydroxysteroid dehydrogenase-1 deficiency or inhibition enhances hepatic myofibroblast activation in murine liver fibrosis. Hepatology (Baltimore, Md). 2018;67(6):2167–2181. doi:10.1002/hep.29734
   Web of Science ®Google Scholar